What trials are currently taking place at the clinic?


Can you tell me what trials are taking place
at the moment? We’ve got a number of drugs trials at the
moment at Leeds General Infirmary. So we’ve got some drugs looking at monoclonal antibodies
and their function is to control your immune system and hopefully to, generally to reduce
the number of circulating white blood cells that can cross the barrier into your brain
and start attacking your brain cells. So we’ve got one at the moment into a drug called Ocrelizumab,
we’re looking at starting another one later in the year. We’ve got a number of trials
looking at, there’s an exciting new drug called Siponimod in secondary progressive
MS. We’ve had some promising results with that, so we’re currently following some
patients through. And we’re also looking at some neuro-protective drugs. So we’re
looking at drugs used for heart failure, we’ve got a drug called Melide [ph], an antidepressant
called Fluoxetine, and a drug called Wilazel [ph]. So we’re looking at potential neuroprotective
roles. So, something different that you would normally use those drugs for. And again, in
the autumn we’re looking at starting a trial into a statin, which again, we’re hoping
actually might be able to have some neuroprotective effects. In addition to that, like I said
before, we’re looking at the experience of MS, so looking at job retention, decision
making processes, the sort of looking more holistically at MS and how people cope with
that. And is there any particular one that you are
really excited about or you think… I think they’re all exciting in their own
way. I think the Ocrelizumab is an exciting one because we’ve had some – we’re not
looking at that in primary progressive MS, however, it has had some exciting results
in other trials in primary progressive MS. We’re looking at that in relapsing remitting
MS and again, that looks promising. Another one that I’m quite excited about actually
is the Siponimod trial, because that’s for secondary progressive MS and we’ve had some
good results with that and we’ve had some, obviously subjectively, a lot of patients
have been pleased in Leeds with the effects of the drug. And I’ve found that particularly
exciting, because for secondary progressive MS patients, there isn’t an awful lot out
there at the moment, so to know that we’re working on something that’s looking promising,
I find that very exciting.

Author Since: Mar 11, 2019

Related Post